Related references
Note: Only part of the references are listed.Design and synthesis of Atglistatin derivatives as adipose triglyceride lipase inhibitors
Jiyu Jin et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2017)
Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles
Xuehai Pang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
Neal D. Shore et al.
LANCET ONCOLOGY (2016)
Preparation and Utility of Organic Pentafluorosulfanyl-Containing Compounds
Paul R. Savoie et al.
CHEMICAL REVIEWS (2015)
Strategies for targeting the androgen receptor axis in prostate cancer
Brett S. Carver
DRUG DISCOVERY TODAY (2014)
ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC)
Dana E. Rathkopf et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
Chuangxing Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
Structure-Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
Michael E. Jung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway
Begona Mellado et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling
Margaret M. Centenera et al.
MOLECULAR ENDOCRINOLOGY (2008)
Androgen activation of the sterol regulatory element-binding protein pathway: Current insights
Hannelore V. Heemers et al.
MOLECULAR ENDOCRINOLOGY (2006)
Share Paper
